Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prime Medicine (PRME) Invested Capital (2021 - 2025)

Prime Medicine filings provide 5 years of Invested Capital readings, the most recent being $120.9 million for Q4 2025.

  • On a quarterly basis, Invested Capital fell 21.08% to $120.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $120.9 million, a 21.08% decrease, with the full-year FY2025 number at $120.9 million, down 21.08% from a year prior.
  • Invested Capital hit $120.9 million in Q4 2025 for Prime Medicine, down from $161.8 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $316.3 million in Q4 2022 to a low of -$223.1 million in Q3 2022.
  • Median Invested Capital over the past 5 years was $143.1 million (2023), compared with a mean of $86.7 million.
  • The widest YoY moves for Invested Capital: up 302.43% in 2022, down 136.29% in 2022.
  • Prime Medicine's Invested Capital stood at -$156.2 million in 2021, then soared by 302.43% to $316.3 million in 2022, then plummeted by 57.92% to $133.1 million in 2023, then grew by 15.09% to $153.1 million in 2024, then dropped by 21.08% to $120.9 million in 2025.
  • The last three reported values for Invested Capital were $120.9 million (Q4 2025), $161.8 million (Q3 2025), and $60.9 million (Q2 2025) per Business Quant data.